Academic Journal
Hepatic zonation determines tumorigenic potential of mutant β-catenin.
| Τίτλος: | Hepatic zonation determines tumorigenic potential of mutant β-catenin. |
|---|---|
| Συγγραφείς: | Raven A; Cancer Research UK Scotland Institute, Glasgow, UK., Gilroy K; Cancer Research UK Scotland Institute, Glasgow, UK., Jin H; Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA., Waldron JA; Cancer Research UK Scotland Institute, Glasgow, UK., Leslie H; School of Cancer Sciences, University of Glasgow, Glasgow, UK., Munro J; Cancer Research UK Scotland Institute, Glasgow, UK., Hall H; Cancer Research UK Scotland Institute, Glasgow, UK., Ridgway RA; Cancer Research UK Scotland Institute, Glasgow, UK., Ford CA; Cancer Research UK Scotland Institute, Glasgow, UK., Gulhan DC; Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA., Vlahov N; Cancer Research UK Scotland Institute, Glasgow, UK., Mills ML; Cancer Research UK Scotland Institute, Glasgow, UK., Hartley A; Cancer Research UK Scotland Institute, Glasgow, UK., Anderson E; Cancer Research UK Scotland Institute, Glasgow, UK., Bryson S; Cancer Research UK Scotland Institute, Glasgow, UK., Sphyris N; Cancer Research UK Scotland Institute, Glasgow, UK., Müller M; Cancer Research UK Scotland Institute, Glasgow, UK., May S; Cancer Research UK Scotland Institute, Glasgow, UK.; School of Cancer Sciences, University of Glasgow, Glasgow, UK., Cadden B; Cancer Research UK Scotland Institute, Glasgow, UK., Nixon C; Cancer Research UK Scotland Institute, Glasgow, UK., Waddell SH; MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK., Guest R; MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.; CRUK Scotland Centre, Glasgow, UK., Boulter L; MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.; CRUK Scotland Centre, Glasgow, UK., Barker N; Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.; Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore., Clevers H; Pharma, Research and Early Development (pRED) of F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Oncode Institute, Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences and University Medical Center, Utrecht, the Netherlands., Zhu H; Children's Research Institute and Children's Research Institute Mouse Genome Engineering Core, University of Texas Southwestern Medical Center, Dallas, TX, USA.; Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA.; Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, USA., Ivaska J; Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland., Strathdee D; Cancer Research UK Scotland Institute, Glasgow, UK., Miller CJ; Cancer Research UK Scotland Institute, Glasgow, UK.; School of Cancer Sciences, University of Glasgow, Glasgow, UK.; CRUK Scotland Centre, Glasgow, UK., Jamieson NB; School of Cancer Sciences, University of Glasgow, Glasgow, UK.; CRUK Scotland Centre, Glasgow, UK., Bushell M; Cancer Research UK Scotland Institute, Glasgow, UK.; School of Cancer Sciences, University of Glasgow, Glasgow, UK., Park PJ; Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA., Bird TG; Cancer Research UK Scotland Institute, Glasgow, UK.; School of Cancer Sciences, University of Glasgow, Glasgow, UK.; CRUK Scotland Centre, Glasgow, UK.; MRC Centre for Inflammation Research, The Queen's Medical Research Institute, University of Edinburgh, Edinburgh, UK., Sansom OJ; Cancer Research UK Scotland Institute, Glasgow, UK. o.sansom@crukscotlandinstitute.ac.uk.; School of Cancer Sciences, University of Glasgow, Glasgow, UK. o.sansom@crukscotlandinstitute.ac.uk.; CRUK Scotland Centre, Glasgow, UK. o.sansom@crukscotlandinstitute.ac.uk. |
| Πηγή: | Nature [Nature] 2026 Jan; Vol. 649 (8097), pp. 739-748. Date of Electronic Publication: 2025 Nov 19. |
| Τύπος έκδοσης: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Nature Publishing Group Country of Publication: England NLM ID: 0410462 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-4687 (Electronic) Linking ISSN: 00280836 NLM ISO Abbreviation: Nature Subsets: MEDLINE |
| Imprint Name(s): | Publication: Basingstoke : Nature Publishing Group Original Publication: London, Macmillan Journals ltd. |
| Ιατρικοί όροι (MeSH): | beta Catenin*/genetics , beta Catenin*/metabolism , Liver*/pathology , Liver*/metabolism , Liver*/cytology , Carcinogenesis*/genetics , Carcinogenesis*/pathology , Mutation*/genetics , Liver Neoplasms*/pathology , Liver Neoplasms*/genetics , Liver Neoplasms*/metabolism , Mutant Proteins*/metabolism , Mutant Proteins*/genetics, Hepatocytes/metabolism ; Hepatocytes/pathology ; Hepatocytes/cytology ; Proto-Oncogene Proteins c-myc/metabolism ; Proto-Oncogene Proteins c-myc/genetics ; TOR Serine-Threonine Kinases/metabolism ; Carcinoma, Hepatocellular/pathology ; Carcinoma, Hepatocellular/genetics ; Cyclin D1/metabolism ; Animals ; Mice ; Wnt Signaling Pathway ; Cell Proliferation ; Cell Differentiation ; Male ; Female ; Alleles ; MAP Kinase Signaling System ; Humans |
| Περίληψη: | Oncogenic mutations in phenotypically normal tissue are common across adult organs1,2. This suggests that multiple events need to converge to drive tumorigenesis and that many processes such as tissue differentiation may protect against carcinogenesis. WNT-β-catenin signalling maintains zonal differentiation during liver homeostasis3,4. However, the CTNNB1 oncogene-encoding β-catenin-is also frequently mutated in hepatocellular carcinoma, resulting in aberrant WNT signalling that promotes cell growth5,6. Here we investigated the antagonistic interplay between WNT-driven growth and differentiation in zonal hepatocyte populations during liver tumorigenesis. We found that β-catenin mutations co-operate with exogenous MYC expression to drive a proliferative translatome. Differentiation of hepatocytes to an extreme zone 3 fate suppressed this proliferative translatome. Furthermore, a GLUL and Lgr5-positive perivenous subpopulation of zone 3 hepatocytes were refractory to WNT-induced and MYC-induced tumorigenesis. However, when mutant CTNNB1 and MYC alleles were activated sporadically across the liver lobule, a subset of mutant hepatocytes became proliferative and tumorigenic. These early lesions were characterized by reduced WNT pathway activation and elevated MAPK signalling, which suppresses zone 3 differentiation. The proliferative lesions were also dependent on IGFBP2-mTOR-cyclin D1 pathway signalling, in which inhibition of either IGFBP2 or mTOR suppressed proliferation and tumorigenesis. Therefore, we propose that zonal identity dictates hepatocyte susceptibility to WNT-driven tumorigenesis and that escaping WNT-induced differentiation is essential for liver cancer. (© 2025. The Author(s).) |
| Competing Interests: | Competing interests: O.J.S. receives funding from Novartis, Cancer Research Technology (Cancer Research Horizons), Boehringer Ingelheim and AstraZeneca for other unrelated projects. H.Z. is a cofounder of Quotient Therapeutics and Jumble Therapeutics, advises for Newlimit, Alnylam Pharmaceuticals and receives funding from Chroma Medicines for other unrelated projects. H.C. is the head of PharmaResearch and Early Development at Roche; full disclosure is available at https://www.uu.nl/staff/JCClevers . M.B. has consulted for BIoNTech. All other authors declare no competing interests. |
| References: | Science. 2021 Feb 26;371(6532):. (PMID: 33632818) EMBO J. 2015 Sep 14;34(18):2321-33. (PMID: 26240067) Gastroenterology. 2012 Dec;143(6):1650-9. (PMID: 22960659) Nat Biotechnol. 2020 May;38(5):586-599. (PMID: 32393914) Nat Methods. 2012 Mar 04;9(4):357-9. (PMID: 22388286) Nat Genet. 2015 May;47(5):505-511. (PMID: 25822088) Nat Commun. 2022 Jan 17;13(1):334. (PMID: 35039505) Proc Natl Acad Sci U S A. 2004 Dec 7;101(49):17216-21. (PMID: 15563600) Nat Genet. 2019 May;51(5):912-919. (PMID: 30988514) Cell Stem Cell. 2021 Oct 7;28(10):1822-1837.e10. (PMID: 34129813) Nature. 2012 Aug 30;488(7413):665-9. (PMID: 22895187) Cell. 2014 Jun 5;157(6):1324-1338. (PMID: 24906150) Science. 2022 Nov 18;378(6621):eabg3679. (PMID: 36395225) Cancer Res. 2002 Apr 1;62(7):1971-7. (PMID: 11929813) N Engl J Med. 2016 Sep 22;375(12):1109-12. (PMID: 27653561) J Hepatol. 2023 May;78(5):1028-1036. (PMID: 36702176) Nat Cell Biol. 2017 Jul;19(7):774-786. (PMID: 28581476) Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14950-5. (PMID: 9843996) Cancer Cell. 2008 Dec 9;14(6):471-84. (PMID: 19061838) Nat Neurosci. 2010 Jan;13(1):133-40. (PMID: 20023653) Nat Biotechnol. 2016 Feb;34(2):155-63. (PMID: 26619011) Bioinformatics. 2020 Jun 1;36(12):3916-3917. (PMID: 32232425) BMC Bioinformatics. 2013 Apr 15;14:128. (PMID: 23586463) Genome Biol. 2021 Nov 29;22(1):323. (PMID: 34844637) Nature. 2018 Jun;558(7711):605-609. (PMID: 29925953) Genome Biol. 2014;15(12):550. (PMID: 25516281) Immunity. 2001 May;14(5):523-34. (PMID: 11371355) Proc Natl Acad Sci U S A. 2019 Sep 24;116(39):19530-19540. (PMID: 31488716) Cell. 2017 Jun 15;169(7):1327-1341.e23. (PMID: 28622513) Science. 2015 May 22;348(6237):880-6. (PMID: 25999502) Nat Commun. 2019 Feb 13;10(1):723. (PMID: 30760720) Nature. 2019 Oct;574(7779):538-542. (PMID: 31645727) Genesis. 2004 Jul;39(3):186-93. (PMID: 15282745) Nat Methods. 2012 Jun 28;9(7):676-82. (PMID: 22743772) PLoS Genet. 2013 Mar;9(3):e1003380. (PMID: 23555292) Hepatology. 2019 Feb;69(2):742-759. (PMID: 30215850) Cancer Res. 2009 Sep 15;69(18):7385-92. (PMID: 19723656) Hepatology. 2020 Oct;72(4):1430-1443. (PMID: 31965581) Cancers (Basel). 2023 Aug 05;15(15):. (PMID: 37568801) Cancer Cell. 2013 Jul 8;24(1):15-29. (PMID: 23845441) Drug Metab Dispos. 2007 Apr;35(4):503-7. (PMID: 17220236) Gastroenterology. 2009 Jun;136(7):2316-2324.e1-3. (PMID: 19268669) Cell Syst. 2015 Dec 23;1(6):417-425. (PMID: 26771021) Nature. 2017 Feb 16;542(7641):352-356. (PMID: 28166538) Cell Stem Cell. 2023 May 4;30(5):665-676.e4. (PMID: 37146585) PLoS Genet. 2010 Jan 15;6(1):e1000816. (PMID: 20084116) BMC Bioinformatics. 2011 Aug 04;12:323. (PMID: 21816040) Nat Genet. 2024 May;56(5):953-969. (PMID: 38627598) Physiol Genomics. 2007 Sep 19;31(1):32-41. (PMID: 17456738) Dev Cell. 2018 Feb 26;44(4):447-459.e5. (PMID: 29429824) Hepatology. 2014 Dec;60(6):1972-82. (PMID: 24798001) Science. 1997 Oct 3;278(5335):120-3. (PMID: 9311916) Hum Mol Genet. 2002 Jun 15;11(13):1549-60. (PMID: 12045208) J Hepatol. 2018 Oct;69(4):840-850. (PMID: 29958939) JHEP Rep. 2021 May 27;3(4):100315. (PMID: 34345813) Nature. 2015 Jan 22;517(7535):497-500. (PMID: 25383520) Genome Res. 2017 Mar;27(3):491-499. (PMID: 28100584) Cancer Res. 2005 Dec 15;65(24):11493-500. (PMID: 16357158) Nat Commun. 2021 Jan 28;12(1):646. (PMID: 33510149) Cell Rep. 2015 Mar 17;10(10):1692-1707. (PMID: 25772357) Cell Stem Cell. 2022 Mar 3;29(3):372-385.e8. (PMID: 35090595) EMBO J. 1999 Nov 1;18(21):5931-42. (PMID: 10545105) Nat Cell Biol. 2016 May;18(5):467-79. (PMID: 27088858) Hepatol Commun. 2018 Jun 21;2(7):845-860. (PMID: 30027142) Science. 2021 Feb 26;371(6532):. (PMID: 33632818) J Hepatol. 2005 Jun;42(6):842-9. (PMID: 15885355) Sci Transl Med. 2018 Jun 20;10(446):. (PMID: 29925636) Hepatology. 2016 Dec;64(6):2047-2061. (PMID: 27177928) |
| Grant Information: | United Kingdom WT_ Wellcome Trust; R01 AA028791 United States AA NIAAA NIH HHS; R01 CA251928 United States CA NCI NIH HHS |
| Substance Nomenclature: | 0 (beta Catenin) 0 (Proto-Oncogene Proteins c-myc) EC 2.7.11.1 (TOR Serine-Threonine Kinases) 0 (CTNNB1 protein, mouse) 0 (Mutant Proteins) 0 (Myc protein, mouse) EC 2.7.1.1 (mTOR protein, mouse) 136601-57-5 (Cyclin D1) |
| Entry Date(s): | Date Created: 20251119 Date Completed: 20260114 Latest Revision: 20260420 |
| Update Code: | 20260420 |
| PubMed Central ID: | PMC12804091 |
| DOI: | 10.1038/s41586-025-09733-1 |
| PMID: | 41261129 |
| Βάση Δεδομένων: | MEDLINE |
| FullText | Text: Availability: 0 CustomLinks: – Url: https://dx.doi.org/doi:10.1038/s41586-025-09733-1 Name: EDS - Springer Nature Journals (s7799221) Category: fullText Text: View record at Springer – Url: https://resolver.ebsco.com/c/fiv2js/result?sid=EBSCO:cmedm&genre=article&issn=14764687&ISBN=&volume=649&issue=8097&date=20260101&spage=739&pages=739-748&title=Nature&atitle=Hepatic%20zonation%20determines%20tumorigenic%20potential%20of%20mutant%20%CE%B2-catenin.&aulast=Raven%20A&id=DOI:10.1038/s41586-025-09733-1 Name: Full Text Finder (for New FTF UI) (ns324271) Category: fullText Text: Full Text Finder MouseOverText: Full Text Finder |
|---|---|
| Header | DbId: cmedm DbLabel: MEDLINE An: 41261129 AccessLevel: 3 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Hepatic zonation determines tumorigenic potential of mutant β-catenin. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Raven+A%22">Raven A</searchLink>; Cancer Research UK Scotland Institute, Glasgow, UK.<br /><searchLink fieldCode="AU" term="%22Gilroy+K%22">Gilroy K</searchLink>; Cancer Research UK Scotland Institute, Glasgow, UK.<br /><searchLink fieldCode="AU" term="%22Jin+H%22">Jin H</searchLink>; Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Waldron+JA%22">Waldron JA</searchLink>; Cancer Research UK Scotland Institute, Glasgow, UK.<br /><searchLink fieldCode="AU" term="%22Leslie+H%22">Leslie H</searchLink>; School of Cancer Sciences, University of Glasgow, Glasgow, UK.<br /><searchLink fieldCode="AU" term="%22Munro+J%22">Munro J</searchLink>; Cancer Research UK Scotland Institute, Glasgow, UK.<br /><searchLink fieldCode="AU" term="%22Hall+H%22">Hall H</searchLink>; Cancer Research UK Scotland Institute, Glasgow, UK.<br /><searchLink fieldCode="AU" term="%22Ridgway+RA%22">Ridgway RA</searchLink>; Cancer Research UK Scotland Institute, Glasgow, UK.<br /><searchLink fieldCode="AU" term="%22Ford+CA%22">Ford CA</searchLink>; Cancer Research UK Scotland Institute, Glasgow, UK.<br /><searchLink fieldCode="AU" term="%22Gulhan+DC%22">Gulhan DC</searchLink>; Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Vlahov+N%22">Vlahov N</searchLink>; Cancer Research UK Scotland Institute, Glasgow, UK.<br /><searchLink fieldCode="AU" term="%22Mills+ML%22">Mills ML</searchLink>; Cancer Research UK Scotland Institute, Glasgow, UK.<br /><searchLink fieldCode="AU" term="%22Hartley+A%22">Hartley A</searchLink>; Cancer Research UK Scotland Institute, Glasgow, UK.<br /><searchLink fieldCode="AU" term="%22Anderson+E%22">Anderson E</searchLink>; Cancer Research UK Scotland Institute, Glasgow, UK.<br /><searchLink fieldCode="AU" term="%22Bryson+S%22">Bryson S</searchLink>; Cancer Research UK Scotland Institute, Glasgow, UK.<br /><searchLink fieldCode="AU" term="%22Sphyris+N%22">Sphyris N</searchLink>; Cancer Research UK Scotland Institute, Glasgow, UK.<br /><searchLink fieldCode="AU" term="%22Müller+M%22">Müller M</searchLink>; Cancer Research UK Scotland Institute, Glasgow, UK.<br /><searchLink fieldCode="AU" term="%22May+S%22">May S</searchLink>; Cancer Research UK Scotland Institute, Glasgow, UK.; School of Cancer Sciences, University of Glasgow, Glasgow, UK.<br /><searchLink fieldCode="AU" term="%22Cadden+B%22">Cadden B</searchLink>; Cancer Research UK Scotland Institute, Glasgow, UK.<br /><searchLink fieldCode="AU" term="%22Nixon+C%22">Nixon C</searchLink>; Cancer Research UK Scotland Institute, Glasgow, UK.<br /><searchLink fieldCode="AU" term="%22Waddell+SH%22">Waddell SH</searchLink>; MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.<br /><searchLink fieldCode="AU" term="%22Guest+R%22">Guest R</searchLink>; MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.; CRUK Scotland Centre, Glasgow, UK.<br /><searchLink fieldCode="AU" term="%22Boulter+L%22">Boulter L</searchLink>; MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.; CRUK Scotland Centre, Glasgow, UK.<br /><searchLink fieldCode="AU" term="%22Barker+N%22">Barker N</searchLink>; Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.; Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.<br /><searchLink fieldCode="AU" term="%22Clevers+H%22">Clevers H</searchLink>; Pharma, Research and Early Development (pRED) of F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Oncode Institute, Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences and University Medical Center, Utrecht, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Zhu+H%22">Zhu H</searchLink>; Children's Research Institute and Children's Research Institute Mouse Genome Engineering Core, University of Texas Southwestern Medical Center, Dallas, TX, USA.; Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA.; Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, USA.<br /><searchLink fieldCode="AU" term="%22Ivaska+J%22">Ivaska J</searchLink>; Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.<br /><searchLink fieldCode="AU" term="%22Strathdee+D%22">Strathdee D</searchLink>; Cancer Research UK Scotland Institute, Glasgow, UK.<br /><searchLink fieldCode="AU" term="%22Miller+CJ%22">Miller CJ</searchLink>; Cancer Research UK Scotland Institute, Glasgow, UK.; School of Cancer Sciences, University of Glasgow, Glasgow, UK.; CRUK Scotland Centre, Glasgow, UK.<br /><searchLink fieldCode="AU" term="%22Jamieson+NB%22">Jamieson NB</searchLink>; School of Cancer Sciences, University of Glasgow, Glasgow, UK.; CRUK Scotland Centre, Glasgow, UK.<br /><searchLink fieldCode="AU" term="%22Bushell+M%22">Bushell M</searchLink>; Cancer Research UK Scotland Institute, Glasgow, UK.; School of Cancer Sciences, University of Glasgow, Glasgow, UK.<br /><searchLink fieldCode="AU" term="%22Park+PJ%22">Park PJ</searchLink>; Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Bird+TG%22">Bird TG</searchLink>; Cancer Research UK Scotland Institute, Glasgow, UK.; School of Cancer Sciences, University of Glasgow, Glasgow, UK.; CRUK Scotland Centre, Glasgow, UK.; MRC Centre for Inflammation Research, The Queen's Medical Research Institute, University of Edinburgh, Edinburgh, UK.<br /><searchLink fieldCode="AU" term="%22Sansom+OJ%22">Sansom OJ</searchLink>; Cancer Research UK Scotland Institute, Glasgow, UK. o.sansom@crukscotlandinstitute.ac.uk.; School of Cancer Sciences, University of Glasgow, Glasgow, UK. o.sansom@crukscotlandinstitute.ac.uk.; CRUK Scotland Centre, Glasgow, UK. o.sansom@crukscotlandinstitute.ac.uk. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%220410462%22">Nature</searchLink> [Nature] 2026 Jan; Vol. 649 (8097), pp. 739-748. <i>Date of Electronic Publication: </i>2025 Nov 19. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't – Name: Language Label: Language Group: Lang Data: English – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Publishing+Group%22">Nature Publishing Group </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>0410462 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1476-4687 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200280836%22">00280836 </searchLink><i>NLM ISO Abbreviation: </i>Nature <i>Subsets: </i>MEDLINE – Name: PublisherInfo Label: Imprint Name(s) Group: PubInfo Data: <i>Publication</i>: Basingstoke : Nature Publishing Group<br /><i>Original Publication</i>: London, Macmillan Journals ltd. – Name: SubjectMESH Label: MeSH Terms Group: Su Data: <searchLink fieldCode="MM" term="%22beta+Catenin%22">beta Catenin*</searchLink>/<searchLink fieldCode="MM" term="%22beta+Catenin+genetics%22">genetics</searchLink> <br /><searchLink fieldCode="MM" term="%22beta+Catenin%22">beta Catenin*</searchLink>/<searchLink fieldCode="MM" term="%22beta+Catenin+metabolism%22">metabolism</searchLink> <br /><searchLink fieldCode="MM" term="%22Liver%22">Liver*</searchLink>/<searchLink fieldCode="MM" term="%22Liver+pathology%22">pathology</searchLink> <br /><searchLink fieldCode="MM" term="%22Liver%22">Liver*</searchLink>/<searchLink fieldCode="MM" term="%22Liver+metabolism%22">metabolism</searchLink> <br /><searchLink fieldCode="MM" term="%22Liver%22">Liver*</searchLink>/<searchLink fieldCode="MM" term="%22Liver+cytology%22">cytology</searchLink> <br /><searchLink fieldCode="MM" term="%22Carcinogenesis%22">Carcinogenesis*</searchLink>/<searchLink fieldCode="MM" term="%22Carcinogenesis+genetics%22">genetics</searchLink> <br /><searchLink fieldCode="MM" term="%22Carcinogenesis%22">Carcinogenesis*</searchLink>/<searchLink fieldCode="MM" term="%22Carcinogenesis+pathology%22">pathology</searchLink> <br /><searchLink fieldCode="MM" term="%22Mutation%22">Mutation*</searchLink>/<searchLink fieldCode="MM" term="%22Mutation+genetics%22">genetics</searchLink> <br /><searchLink fieldCode="MM" term="%22Liver+Neoplasms%22">Liver Neoplasms*</searchLink>/<searchLink fieldCode="MM" term="%22Liver+Neoplasms+pathology%22">pathology</searchLink> <br /><searchLink fieldCode="MM" term="%22Liver+Neoplasms%22">Liver Neoplasms*</searchLink>/<searchLink fieldCode="MM" term="%22Liver+Neoplasms+genetics%22">genetics</searchLink> <br /><searchLink fieldCode="MM" term="%22Liver+Neoplasms%22">Liver Neoplasms*</searchLink>/<searchLink fieldCode="MM" term="%22Liver+Neoplasms+metabolism%22">metabolism</searchLink> <br /><searchLink fieldCode="MM" term="%22Mutant+Proteins%22">Mutant Proteins*</searchLink>/<searchLink fieldCode="MM" term="%22Mutant+Proteins+metabolism%22">metabolism</searchLink> <br /><searchLink fieldCode="MM" term="%22Mutant+Proteins%22">Mutant Proteins*</searchLink>/<searchLink fieldCode="MM" term="%22Mutant+Proteins+genetics%22">genetics</searchLink><br /><searchLink fieldCode="MH" term="%22Hepatocytes%22">Hepatocytes</searchLink>/<searchLink fieldCode="MH" term="%22Hepatocytes+metabolism%22">metabolism</searchLink> ; <searchLink fieldCode="MH" term="%22Hepatocytes%22">Hepatocytes</searchLink>/<searchLink fieldCode="MH" term="%22Hepatocytes+pathology%22">pathology</searchLink> ; <searchLink fieldCode="MH" term="%22Hepatocytes%22">Hepatocytes</searchLink>/<searchLink fieldCode="MH" term="%22Hepatocytes+cytology%22">cytology</searchLink> ; <searchLink fieldCode="MH" term="%22Proto-Oncogene+Proteins+c-myc%22">Proto-Oncogene Proteins c-myc</searchLink>/<searchLink fieldCode="MH" term="%22Proto-Oncogene+Proteins+c-myc+metabolism%22">metabolism</searchLink> ; <searchLink fieldCode="MH" term="%22Proto-Oncogene+Proteins+c-myc%22">Proto-Oncogene Proteins c-myc</searchLink>/<searchLink fieldCode="MH" term="%22Proto-Oncogene+Proteins+c-myc+genetics%22">genetics</searchLink> ; <searchLink fieldCode="MH" term="%22TOR+Serine-Threonine+Kinases%22">TOR Serine-Threonine Kinases</searchLink>/<searchLink fieldCode="MH" term="%22TOR+Serine-Threonine+Kinases+metabolism%22">metabolism</searchLink> ; <searchLink fieldCode="MH" term="%22Carcinoma%2C+Hepatocellular%22">Carcinoma, Hepatocellular</searchLink>/<searchLink fieldCode="MH" term="%22Carcinoma%2C+Hepatocellular+pathology%22">pathology</searchLink> ; <searchLink fieldCode="MH" term="%22Carcinoma%2C+Hepatocellular%22">Carcinoma, Hepatocellular</searchLink>/<searchLink fieldCode="MH" term="%22Carcinoma%2C+Hepatocellular+genetics%22">genetics</searchLink> ; <searchLink fieldCode="MH" term="%22Cyclin+D1%22">Cyclin D1</searchLink>/<searchLink fieldCode="MH" term="%22Cyclin+D1+metabolism%22">metabolism</searchLink> ; <searchLink fieldCode="MH" term="%22Animals%22">Animals</searchLink> ; <searchLink fieldCode="MH" term="%22Mice%22">Mice</searchLink> ; <searchLink fieldCode="MH" term="%22Wnt+Signaling+Pathway%22">Wnt Signaling Pathway</searchLink> ; <searchLink fieldCode="MH" term="%22Cell+Proliferation%22">Cell Proliferation</searchLink> ; <searchLink fieldCode="MH" term="%22Cell+Differentiation%22">Cell Differentiation</searchLink> ; <searchLink fieldCode="MH" term="%22Male%22">Male</searchLink> ; <searchLink fieldCode="MH" term="%22Female%22">Female</searchLink> ; <searchLink fieldCode="MH" term="%22Alleles%22">Alleles</searchLink> ; <searchLink fieldCode="MH" term="%22MAP+Kinase+Signaling+System%22">MAP Kinase Signaling System</searchLink> ; <searchLink fieldCode="MH" term="%22Humans%22">Humans</searchLink> – Name: Abstract Label: Abstract Group: Ab Data: Oncogenic mutations in phenotypically normal tissue are common across adult organs<superscript>1,2</superscript>. This suggests that multiple events need to converge to drive tumorigenesis and that many processes such as tissue differentiation may protect against carcinogenesis. WNT-β-catenin signalling maintains zonal differentiation during liver homeostasis<superscript>3,4</superscript>. However, the CTNNB1 oncogene-encoding β-catenin-is also frequently mutated in hepatocellular carcinoma, resulting in aberrant WNT signalling that promotes cell growth<superscript>5,6</superscript>. Here we investigated the antagonistic interplay between WNT-driven growth and differentiation in zonal hepatocyte populations during liver tumorigenesis. We found that β-catenin mutations co-operate with exogenous MYC expression to drive a proliferative translatome. Differentiation of hepatocytes to an extreme zone 3 fate suppressed this proliferative translatome. Furthermore, a GLUL and Lgr5-positive perivenous subpopulation of zone 3 hepatocytes were refractory to WNT-induced and MYC-induced tumorigenesis. However, when mutant CTNNB1 and MYC alleles were activated sporadically across the liver lobule, a subset of mutant hepatocytes became proliferative and tumorigenic. These early lesions were characterized by reduced WNT pathway activation and elevated MAPK signalling, which suppresses zone 3 differentiation. The proliferative lesions were also dependent on IGFBP2-mTOR-cyclin D1 pathway signalling, in which inhibition of either IGFBP2 or mTOR suppressed proliferation and tumorigenesis. Therefore, we propose that zonal identity dictates hepatocyte susceptibility to WNT-driven tumorigenesis and that escaping WNT-induced differentiation is essential for liver cancer.<br /> (© 2025. The Author(s).) – Name: Abstract Label: Competing Interests Group: Ab Data: Competing interests: O.J.S. receives funding from Novartis, Cancer Research Technology (Cancer Research Horizons), Boehringer Ingelheim and AstraZeneca for other unrelated projects. H.Z. is a cofounder of Quotient Therapeutics and Jumble Therapeutics, advises for Newlimit, Alnylam Pharmaceuticals and receives funding from Chroma Medicines for other unrelated projects. H.C. is the head of PharmaResearch and Early Development at Roche; full disclosure is available at https://www.uu.nl/staff/JCClevers . M.B. has consulted for BIoNTech. All other authors declare no competing interests. – Name: Ref Label: References Group: RefInfo Data: Science. 2021 Feb 26;371(6532):. (PMID: <searchLink fieldCode="PM" term="%2233632818%22">33632818)</searchLink><br />EMBO J. 2015 Sep 14;34(18):2321-33. (PMID: <searchLink fieldCode="PM" term="%2226240067%22">26240067)</searchLink><br />Gastroenterology. 2012 Dec;143(6):1650-9. (PMID: <searchLink fieldCode="PM" term="%2222960659%22">22960659)</searchLink><br />Nat Biotechnol. 2020 May;38(5):586-599. (PMID: <searchLink fieldCode="PM" term="%2232393914%22">32393914)</searchLink><br />Nat Methods. 2012 Mar 04;9(4):357-9. (PMID: <searchLink fieldCode="PM" term="%2222388286%22">22388286)</searchLink><br />Nat Genet. 2015 May;47(5):505-511. (PMID: <searchLink fieldCode="PM" term="%2225822088%22">25822088)</searchLink><br />Nat Commun. 2022 Jan 17;13(1):334. (PMID: <searchLink fieldCode="PM" term="%2235039505%22">35039505)</searchLink><br />Proc Natl Acad Sci U S A. 2004 Dec 7;101(49):17216-21. (PMID: <searchLink fieldCode="PM" term="%2215563600%22">15563600)</searchLink><br />Nat Genet. 2019 May;51(5):912-919. (PMID: <searchLink fieldCode="PM" term="%2230988514%22">30988514)</searchLink><br />Cell Stem Cell. 2021 Oct 7;28(10):1822-1837.e10. (PMID: <searchLink fieldCode="PM" term="%2234129813%22">34129813)</searchLink><br />Nature. 2012 Aug 30;488(7413):665-9. (PMID: <searchLink fieldCode="PM" term="%2222895187%22">22895187)</searchLink><br />Cell. 2014 Jun 5;157(6):1324-1338. (PMID: <searchLink fieldCode="PM" term="%2224906150%22">24906150)</searchLink><br />Science. 2022 Nov 18;378(6621):eabg3679. (PMID: <searchLink fieldCode="PM" term="%2236395225%22">36395225)</searchLink><br />Cancer Res. 2002 Apr 1;62(7):1971-7. (PMID: <searchLink fieldCode="PM" term="%2211929813%22">11929813)</searchLink><br />N Engl J Med. 2016 Sep 22;375(12):1109-12. (PMID: <searchLink fieldCode="PM" term="%2227653561%22">27653561)</searchLink><br />J Hepatol. 2023 May;78(5):1028-1036. (PMID: <searchLink fieldCode="PM" term="%2236702176%22">36702176)</searchLink><br />Nat Cell Biol. 2017 Jul;19(7):774-786. (PMID: <searchLink fieldCode="PM" term="%2228581476%22">28581476)</searchLink><br />Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14950-5. (PMID: <searchLink fieldCode="PM" term="%229843996%22">9843996)</searchLink><br />Cancer Cell. 2008 Dec 9;14(6):471-84. (PMID: <searchLink fieldCode="PM" term="%2219061838%22">19061838)</searchLink><br />Nat Neurosci. 2010 Jan;13(1):133-40. (PMID: <searchLink fieldCode="PM" term="%2220023653%22">20023653)</searchLink><br />Nat Biotechnol. 2016 Feb;34(2):155-63. (PMID: <searchLink fieldCode="PM" term="%2226619011%22">26619011)</searchLink><br />Bioinformatics. 2020 Jun 1;36(12):3916-3917. (PMID: <searchLink fieldCode="PM" term="%2232232425%22">32232425)</searchLink><br />BMC Bioinformatics. 2013 Apr 15;14:128. (PMID: <searchLink fieldCode="PM" term="%2223586463%22">23586463)</searchLink><br />Genome Biol. 2021 Nov 29;22(1):323. (PMID: <searchLink fieldCode="PM" term="%2234844637%22">34844637)</searchLink><br />Nature. 2018 Jun;558(7711):605-609. (PMID: <searchLink fieldCode="PM" term="%2229925953%22">29925953)</searchLink><br />Genome Biol. 2014;15(12):550. (PMID: <searchLink fieldCode="PM" term="%2225516281%22">25516281)</searchLink><br />Immunity. 2001 May;14(5):523-34. (PMID: <searchLink fieldCode="PM" term="%2211371355%22">11371355)</searchLink><br />Proc Natl Acad Sci U S A. 2019 Sep 24;116(39):19530-19540. (PMID: <searchLink fieldCode="PM" term="%2231488716%22">31488716)</searchLink><br />Cell. 2017 Jun 15;169(7):1327-1341.e23. (PMID: <searchLink fieldCode="PM" term="%2228622513%22">28622513)</searchLink><br />Science. 2015 May 22;348(6237):880-6. (PMID: <searchLink fieldCode="PM" term="%2225999502%22">25999502)</searchLink><br />Nat Commun. 2019 Feb 13;10(1):723. (PMID: <searchLink fieldCode="PM" term="%2230760720%22">30760720)</searchLink><br />Nature. 2019 Oct;574(7779):538-542. (PMID: <searchLink fieldCode="PM" term="%2231645727%22">31645727)</searchLink><br />Genesis. 2004 Jul;39(3):186-93. (PMID: <searchLink fieldCode="PM" term="%2215282745%22">15282745)</searchLink><br />Nat Methods. 2012 Jun 28;9(7):676-82. (PMID: <searchLink fieldCode="PM" term="%2222743772%22">22743772)</searchLink><br />PLoS Genet. 2013 Mar;9(3):e1003380. (PMID: <searchLink fieldCode="PM" term="%2223555292%22">23555292)</searchLink><br />Hepatology. 2019 Feb;69(2):742-759. (PMID: <searchLink fieldCode="PM" term="%2230215850%22">30215850)</searchLink><br />Cancer Res. 2009 Sep 15;69(18):7385-92. (PMID: <searchLink fieldCode="PM" term="%2219723656%22">19723656)</searchLink><br />Hepatology. 2020 Oct;72(4):1430-1443. (PMID: <searchLink fieldCode="PM" term="%2231965581%22">31965581)</searchLink><br />Cancers (Basel). 2023 Aug 05;15(15):. (PMID: <searchLink fieldCode="PM" term="%2237568801%22">37568801)</searchLink><br />Cancer Cell. 2013 Jul 8;24(1):15-29. (PMID: <searchLink fieldCode="PM" term="%2223845441%22">23845441)</searchLink><br />Drug Metab Dispos. 2007 Apr;35(4):503-7. (PMID: <searchLink fieldCode="PM" term="%2217220236%22">17220236)</searchLink><br />Gastroenterology. 2009 Jun;136(7):2316-2324.e1-3. (PMID: <searchLink fieldCode="PM" term="%2219268669%22">19268669)</searchLink><br />Cell Syst. 2015 Dec 23;1(6):417-425. (PMID: <searchLink fieldCode="PM" term="%2226771021%22">26771021)</searchLink><br />Nature. 2017 Feb 16;542(7641):352-356. (PMID: <searchLink fieldCode="PM" term="%2228166538%22">28166538)</searchLink><br />Cell Stem Cell. 2023 May 4;30(5):665-676.e4. (PMID: <searchLink fieldCode="PM" term="%2237146585%22">37146585)</searchLink><br />PLoS Genet. 2010 Jan 15;6(1):e1000816. (PMID: <searchLink fieldCode="PM" term="%2220084116%22">20084116)</searchLink><br />BMC Bioinformatics. 2011 Aug 04;12:323. (PMID: <searchLink fieldCode="PM" term="%2221816040%22">21816040)</searchLink><br />Nat Genet. 2024 May;56(5):953-969. (PMID: <searchLink fieldCode="PM" term="%2238627598%22">38627598)</searchLink><br />Physiol Genomics. 2007 Sep 19;31(1):32-41. (PMID: <searchLink fieldCode="PM" term="%2217456738%22">17456738)</searchLink><br />Dev Cell. 2018 Feb 26;44(4):447-459.e5. (PMID: <searchLink fieldCode="PM" term="%2229429824%22">29429824)</searchLink><br />Hepatology. 2014 Dec;60(6):1972-82. (PMID: <searchLink fieldCode="PM" term="%2224798001%22">24798001)</searchLink><br />Science. 1997 Oct 3;278(5335):120-3. (PMID: <searchLink fieldCode="PM" term="%229311916%22">9311916)</searchLink><br />Hum Mol Genet. 2002 Jun 15;11(13):1549-60. (PMID: <searchLink fieldCode="PM" term="%2212045208%22">12045208)</searchLink><br />J Hepatol. 2018 Oct;69(4):840-850. (PMID: <searchLink fieldCode="PM" term="%2229958939%22">29958939)</searchLink><br />JHEP Rep. 2021 May 27;3(4):100315. (PMID: <searchLink fieldCode="PM" term="%2234345813%22">34345813)</searchLink><br />Nature. 2015 Jan 22;517(7535):497-500. (PMID: <searchLink fieldCode="PM" term="%2225383520%22">25383520)</searchLink><br />Genome Res. 2017 Mar;27(3):491-499. (PMID: <searchLink fieldCode="PM" term="%2228100584%22">28100584)</searchLink><br />Cancer Res. 2005 Dec 15;65(24):11493-500. (PMID: <searchLink fieldCode="PM" term="%2216357158%22">16357158)</searchLink><br />Nat Commun. 2021 Jan 28;12(1):646. (PMID: <searchLink fieldCode="PM" term="%2233510149%22">33510149)</searchLink><br />Cell Rep. 2015 Mar 17;10(10):1692-1707. (PMID: <searchLink fieldCode="PM" term="%2225772357%22">25772357)</searchLink><br />Cell Stem Cell. 2022 Mar 3;29(3):372-385.e8. (PMID: <searchLink fieldCode="PM" term="%2235090595%22">35090595)</searchLink><br />EMBO J. 1999 Nov 1;18(21):5931-42. (PMID: <searchLink fieldCode="PM" term="%2210545105%22">10545105)</searchLink><br />Nat Cell Biol. 2016 May;18(5):467-79. (PMID: <searchLink fieldCode="PM" term="%2227088858%22">27088858)</searchLink><br />Hepatol Commun. 2018 Jun 21;2(7):845-860. (PMID: <searchLink fieldCode="PM" term="%2230027142%22">30027142)</searchLink><br />Science. 2021 Feb 26;371(6532):. (PMID: <searchLink fieldCode="PM" term="%2233632818%22">33632818)</searchLink><br />J Hepatol. 2005 Jun;42(6):842-9. (PMID: <searchLink fieldCode="PM" term="%2215885355%22">15885355)</searchLink><br />Sci Transl Med. 2018 Jun 20;10(446):. (PMID: <searchLink fieldCode="PM" term="%2229925636%22">29925636)</searchLink><br />Hepatology. 2016 Dec;64(6):2047-2061. (PMID: <searchLink fieldCode="PM" term="%2227177928%22">27177928)</searchLink> – Name: GrantInfo Label: Grant Information Group: Grant Data: United Kingdom WT_ Wellcome Trust; R01 AA028791 United States AA NIAAA NIH HHS; R01 CA251928 United States CA NCI NIH HHS – Name: NumberCAS Label: Substance Nomenclature Group: ID Data: 0 (beta Catenin)<br />0 (Proto-Oncogene Proteins c-myc)<br />EC 2.7.11.1 (TOR Serine-Threonine Kinases)<br />0 (CTNNB1 protein, mouse)<br />0 (Mutant Proteins)<br />0 (Myc protein, mouse)<br />EC 2.7.1.1 (mTOR protein, mouse)<br />136601-57-5 (Cyclin D1) – Name: DateEntry Label: Entry Date(s) Group: Date Data: <i>Date Created: </i>20251119 <i>Date Completed: </i>20260114 <i>Latest Revision: </i>20260420 – Name: DateUpdate Label: Update Code Group: Date Data: 20260420 – Name: PubmedCentralID Label: PubMed Central ID Group: ID Data: PMC12804091 – Name: DOI Label: DOI Group: ID Data: 10.1038/s41586-025-09733-1 – Name: AN Label: PMID Group: ID Data: 41261129 |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=cmedm&AN=41261129 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1038/s41586-025-09733-1 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 739 Subjects: – SubjectFull: Hepatocytes metabolism Type: general – SubjectFull: Hepatocytes pathology Type: general – SubjectFull: Hepatocytes cytology Type: general – SubjectFull: Proto-Oncogene Proteins c-myc metabolism Type: general – SubjectFull: Proto-Oncogene Proteins c-myc genetics Type: general – SubjectFull: TOR Serine-Threonine Kinases metabolism Type: general – SubjectFull: Carcinoma, Hepatocellular pathology Type: general – SubjectFull: Carcinoma, Hepatocellular genetics Type: general – SubjectFull: Cyclin D1 metabolism Type: general – SubjectFull: Animals Type: general – SubjectFull: Mice Type: general – SubjectFull: Wnt Signaling Pathway Type: general – SubjectFull: Cell Proliferation Type: general – SubjectFull: Cell Differentiation Type: general – SubjectFull: Male Type: general – SubjectFull: Female Type: general – SubjectFull: Alleles Type: general – SubjectFull: MAP Kinase Signaling System Type: general – SubjectFull: Humans Type: general – SubjectFull: beta Catenin genetics Type: general – SubjectFull: beta Catenin metabolism Type: general – SubjectFull: Liver pathology Type: general – SubjectFull: Liver metabolism Type: general – SubjectFull: Liver cytology Type: general – SubjectFull: Carcinogenesis genetics Type: general – SubjectFull: Carcinogenesis pathology Type: general – SubjectFull: Mutation genetics Type: general – SubjectFull: Liver Neoplasms pathology Type: general – SubjectFull: Liver Neoplasms genetics Type: general – SubjectFull: Liver Neoplasms metabolism Type: general – SubjectFull: Mutant Proteins metabolism Type: general – SubjectFull: Mutant Proteins genetics Type: general Titles: – TitleFull: Hepatic zonation determines tumorigenic potential of mutant β-catenin. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Raven A – PersonEntity: Name: NameFull: Gilroy K – PersonEntity: Name: NameFull: Jin H – PersonEntity: Name: NameFull: Waldron JA – PersonEntity: Name: NameFull: Leslie H – PersonEntity: Name: NameFull: Munro J – PersonEntity: Name: NameFull: Hall H – PersonEntity: Name: NameFull: Ridgway RA – PersonEntity: Name: NameFull: Ford CA – PersonEntity: Name: NameFull: Gulhan DC – PersonEntity: Name: NameFull: Vlahov N – PersonEntity: Name: NameFull: Mills ML – PersonEntity: Name: NameFull: Hartley A – PersonEntity: Name: NameFull: Anderson E – PersonEntity: Name: NameFull: Bryson S – PersonEntity: Name: NameFull: Sphyris N – PersonEntity: Name: NameFull: Müller M – PersonEntity: Name: NameFull: May S – PersonEntity: Name: NameFull: Cadden B – PersonEntity: Name: NameFull: Nixon C – PersonEntity: Name: NameFull: Waddell SH – PersonEntity: Name: NameFull: Guest R – PersonEntity: Name: NameFull: Boulter L – PersonEntity: Name: NameFull: Barker N – PersonEntity: Name: NameFull: Clevers H – PersonEntity: Name: NameFull: Zhu H – PersonEntity: Name: NameFull: Ivaska J – PersonEntity: Name: NameFull: Strathdee D – PersonEntity: Name: NameFull: Miller CJ – PersonEntity: Name: NameFull: Jamieson NB – PersonEntity: Name: NameFull: Bushell M – PersonEntity: Name: NameFull: Park PJ – PersonEntity: Name: NameFull: Bird TG – PersonEntity: Name: NameFull: Sansom OJ IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 01 Text: 2026 Jan Type: published Y: 2026 Identifiers: – Type: issn-electronic Value: 1476-4687 Numbering: – Type: volume Value: 649 – Type: issue Value: 8097 Titles: – TitleFull: Nature Type: main |
| ResultId | 1 |